Codagenix

Codagenix is a biotechnology company that develops live-attenuated viral vaccines using its proprietary SAVE (Synthetic Attenuated Virus Engineering) platform, which relies on synthetic biology and computer-aided redesign of the target virus entire genome to yield vaccine strains. The SAVE platform recodes viral genomes by strategically altering codon usage without changing the encoded proteins, creating attenuated viruses that replicate sufficiently to trigger immune responses but are too weak to cause disease. Codagenix pipeline includes vaccine candidates targeting seasonal influenza, dengue virus, respiratory syncytial virus (RSV), and other infectious diseases, with candidates in preclinical and clinical development stages. The company approach enables rapid vaccine design and manufacturing scalability compared to traditional vaccine development methods. Founded in 2011 and headquartered in Stony Brook, New York, Codagenix has raised $47.1 million through Series B funding from investors including Adjuvant Capital, Serum Institute of India, Euclidean Capital, and the NIH.